image/svg+xml

Corporate Governance

ISR Immune System Regulation Holding AB (publ)

Org.nr. 559026-7828

BOLAGSORDNING (swe)

§ 1

Bolagets företagsnamn är ISR Immune System Regulation Holding AB (publ).

§ 2 

Styrelsen skall ha sitt säte i Stockholms kommun, Stockholms län.

§ 3 

Bolaget skall, direkt eller genom hel- eller delägda dotterbolag, bedriva forskning och utveckling inom det medicinska området, marknadsföra och försälja medicinska tjänster och produkter samt bedriva annan därmed förenlig verksamhet.

§ 4 

Aktiekapitalet skall utgöra lägst 3 000 000 och högst 12 000 000 kronor.

§ 5 

Antalet aktier skall vara lägst 60 000 000 och högst 240 000 000.

§ 6

Styrelsen skall bestå av 3 – 8 ledamöter utan suppleanter.

§ 7

Bolaget skall ha en till två revisorer med eller utan revisorssuppleanter eller ett registrerat revisionsbolag.

§ 8

Kallelse till bolagsstämma ska ske genom annonsering i Post- och Inrikes Tidningar och genom att kallelsen hålls tillgänglig på bolagets webbplats. Att kallelse har skett ska annonseras i Svenska Dagbladet.

Aktieägare som vill delta i bolagsstämma ska göra anmälan härom till bolaget senast den dag som anges i kallelsen till bolagsstämman. Sistnämnda dag får inte vara söndag, annan allmän helgdag, lördag, midsommarafton, julafton eller nyårsafton och inte infalla tidigare än femte vardagen före bolagsstämman.

Aktieägare får vid bolagsstämma medföra ett eller två biträden, dock endast om aktieägaren har anmält detta enligt föregående stycke. 

§ 9 

På årsstämma skall följande ärenden förekomma till behandling:

  1. Val av ordförande vid stämman.

  2. Upprättande och godkännande av röstlängd.

  3. Val av en eller två justeringsmän.

  4. Prövning av om stämman blivit behörigen sammankallad.

  5. Godkännande av dagordning.

  6. Framläggande av årsredovisning och revisionsberättelse samt i förekommande fall koncernredovisning och koncernrevisionsberättelse.

  7. Beslut om:

    a) fastställande av resultaträkning och balansräkning samt i förekommande fall koncernresultaträkning och koncernbalansräkning,

    b) dispositioner beträffande bolagets vinst eller förlust enligt den fastställda balansräkningen,

    c) ansvarsfrihet åt styrelseledamöterna och verkställande direktören.

  1. Fastställande av arvoden till styrelsen och revisorerna.

  2. Val av styrelseledamöter samt av revisorer.

  3. Annat ärende som ankommer på årsstämman enligt aktiebolagslagen (2005:551) eller bolagsordningen.

§ 10

Bolagsstämma kan, förutom där styrelsen har sitt säte, hållas i Solna.

§ 11

Kalenderåret skall vara bolagets räkenskapsår.

§ 12

Bolagets aktier skall vara registrerade i ett avstämningsregister enligt lagen (1998:1479) om värdepapperscentraler och kontoföring av finansiella instrument.

The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on April 27, 2019, at 10:00 at Scandic Continental, Vasagatan 22, 111 20 Stockholm.

ISR Holding 2020 Summon (swe) (PDF) ISR Holding 2020 Proxy form (swe) (PDF) ISR Holding 2020 Minutes of the Annual General Meeting (swe) (PDF)

The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on May 9, 2019, at 14:00 at Günther & Wikberg Fondkommission, Kungsgatan 3, 111 43 Stockholm.

ISR Holding 2019 Summon (swe) (PDF) ISR Holding 2019 Proxy form (swe) (PDF) ISR Holding 2019 Minutes of the Annual General Meeting (swe) (PDF)

The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on May 23, 2018, at 14:00 in Stockholm.

ISR Holding 2018 Minutes of the Annual General Meeting (swe) (PDF)

The Annual General Meeting of ISR Immune System Regulation Holding AB (publ) was held on Thursday, February 9, 2017, at 14.00 at Advokatfirman Nerpin's office, Birger Jarlsgatan 2, 3rd floor in Stockholm.

ISR Holding 2017 Minutes of the Annual General Meeting (swe) (PDF)
Anders-Milton-sv(1)-1655364707.jpg

Anders Milton has a PhD from Uppsala University. Milton has held several different leading positions in both the private and public sector. Including the government's national psychiatric coordinator, chairman of the Swedish Academics' Central Organization (SACO), the Swedish Red Cross and the Swedish Medical Association where he later was CEO. Milton was also a member of the disaster commission that was appointed after the tsunami disaster in 2004. He has led investigations into – among other things – Sweden’s HIV and AIDS policy, organ donation and transplantation, and what society can do to reduce the number of abortions in Sweden.

Other assignments: Chairman of Vironova AB (publ), board member of HumaNova Utbildning AB, and more.

Independent in relation to ISR and the company management and the company's major shareholders.

Gunnar-Jardelov-sv(1)-1655364740.jpg

Gunnar Jardelöv has a degree in economics and a Master of Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Jardelöv has over 50 years of experience from having worked in Sweden and abroad as CEO and member or chairman of several companies. He has developed and led a number of companies that were later sold in industries such as shipping, forwarding, oil storage, real estate, streaming services and IT. Jardelöv is now active as an investor and business angel, as well as, among other things, the assignments listed below.

Other assignments: Chairman of Seamless Distribution Systems AB and Derma Cure Sverige AB.

Independent in relation to ISR and the company management. Not independent in relation to the company's major shareholders.

bengt-fellstrom.jpg

Bengt Fellström, MD, PhD, ex senior professor of medical kidney diseases at Uppsala University. He has been actively working in clinical kidney medicine and research for 35 years with a focus on immunological kidney diseases, transplants and cardiovascular diseases at kidney failure, having published around 270 scientific papers. He has recurrently presented at international medicine conferences.

For 12 years Fellström held positions in the Swedish Research Council, who funds the Swedish research community. Advisor of several pharmaceutical companies and regulatory authorities such as the Swedish Medical Products Agency and FDA. He also led a large number of international clinical trials and cooperated with the international pharmaceutical industry.

Fellström also invented a new treatment for the most common glomerular kidney disease IgA nefrit, the treatment has now been accepted by the recently listed company Calliditas AB, and has been approved for the market by both FDA and EMA. He has also supervised around 15 doctorate students who have successfully defend their dissertations at the university.

Other assignments: Board member of BioAnalogica AB, BioConcept AB, Transcutan AB (suppl), Alimenta Medical AB, Ambryx Invest AB, LillTuna Förvaltning HB.

Erik_beskuren.jpg

Erik Kinnman is an M.D., board certified in Neurology and Pain Management, and has comprehensive scientific qualifications from Karolinska Institutet, which has rendered him a Ph.D. and an Associate Professor. He also holds an Executive MBA from the Stockholm School of Economics.

Erik has 26 years of experience from senior positions in Life Science, including 5 years as CEO of Abliva AB. Furthermore, Erik Kinnman has held senior positions at AstraZeneca and SOBI, among other pharmaceutical and biotech companies, and has been active as a financial analyst at Danske Bank.

Other assignments: CEO of Sprint Bioscience AB (publ), Board member of Stayble AB (publ), Chairman of the Board of Kinnman Solutions AB.

Independent in relation to ISR and the company management and the company's major shareholders.

Ola-Winqvist-sv(1)-1655364918.jpg

Ola Winqvist has more than 30 years of experience in immunological research and is a professor of cellular immunotherapy and chief physician in clinical immunology. He was previously chairman of the Swedish Immunology Association and is now chairman of the Swedish Medical Association's research delegation. The Cancer Foundation and the Swedish Research Council have continuously supported Olas research since 1999. He has also received various competitive grants from the European Union and the Swedish Agency for Innovation Systems for the Development of Immunological Therapy. Ola Winqvist is a specialist and Chief Physician in Clinical Immunology and has a doctorate from Uppsala University in Sweden. He has more than 30 patents and has started several spin-off companies. In 2013, his research was awarded the Athena Prize.

Other assignments: Chairman of the Delegation for research at the Swedish Medical Association and ImmunoWise AB. Board member of, among others, TLA Targeted Immunotherapies AB.

Jonas-Winqvist-sv(1)-1655364969.jpg

Hired as a consultant from Implement Consulting Group. Previous experience as an accountant and management consultant with a focus on organizational and business development.

Johan-1655365087.jpg

Johan Sjödahl has a MSc in Chemical engineering and a PhD in Analytical Chemistry from the Royal Institute of Technology in Stockholm. He has been 25 years in the Life Science field and has experiences from pharmaceutical and medtech product development from BioArctic, Bactiguard and Orkla.

Sven-sv(1)-1655365151.jpg

Dr. Rohmann received his MD from the University of Mainz, Germany, and his PhD from the Erasmus University of Rotterdam, Netherlands. He is significantly experienced in M&A and the pharmacutical industry, and spend 10 years at Merck Serono.

Dr Rohmann was also a Managing Partner of Nextech Venture in Switzerland, as well as responsible as Venture Capital Fund Manager for a Novartis Pharma AG. From 2010 to 2014 he was General Manager Europe for Burill & co, a Helthcare Venture Fund with more than $1.5 billion (USD) under management.

Jacob_Harker-sv(1)-1655365202.jpg

Jacob Harker has a BSc from University of Swansea, Great Britain. He has significant experience in the development of inhaled medicines with more than 20 years of industrial experience from Pfizer, AstraZeneca, PowderJect and Circassia. He also has extensive experience in leading CMC programmes, with focus on formulating and developing medicines by the means of particle technology for delivery via lungs, nasally and through the skin.

Nigel_Goodman-sv(1)-1655365248.jpg

Nigel Goodman has a BSc in Pharmacology, Physiology and Microbiology from the University of Liverpool as well as a MBA from Manchester. He has a significant background in the development of innovative medicines with more than 35 years of industrial experience, from Hoffmann-La Roche in Great Britain and globally, and an American CRO. Since founding Gaea in 1994, and as the CEO of GaeaOÜ, a CRO based in Estonia, he has obtained extensive experience of the design and realization of global clinical studies for biotechnology companies.

Sayad-Sahahjahan_beskuren.jpg

CEO Singapore Ltd. An international businessman that is the advisor to the government of Moldavia. vice president of international affair TLA and CarryGenes

Accountant
PWC
Chartered Accountant: Magnus Lagerberg
magnus.lagerberg@pwc.com
010-212 59 55

Subscribe to news and pressreleases

Language
Information Type